Biannual versus annual mass azithromycin distribution and malaria seroepidemiology among preschool children in Niger: a sub-study of a cluster randomized trial

Catherine E. Oldenburg1,2,3*, Abdou Amza4, Gretchen Cooley5, Boubacar Kadri4, Beido Nassirou4, Benjamin F. Arnold6, Philip J. Rosenthal7, Kieran S. O’Brien1,6, Sheila K. West8, Robin L. Bailey9, Travis C. Porco1,2,3, Jeremy D. Keenan1,2, Thomas M. Lietman1,2,3 and Diana L. Martin5

Abstract

Background: Biannual mass azithromycin administration to preschool children reduces all-cause mortality, but the mechanism for the effect is not understood. Azithromycin has activity against malaria parasites, and malaria is a leading cause of child mortality in the Sahel. The effect of biannual versus annual azithromycin distribution for trachoma control on serological response to merozoite surface protein 1 (MSP-119), a surrogate for malaria incidence, was evaluated among children in Niger.

Methods: Markers of malaria exposure were measured in two arms of a factorial randomized controlled trial designed to evaluate targeted biannual azithromycin distribution to children under 12 years of age compared to annual azithromycin to the entire community for trachoma control (N = 12 communities per arm). Communities were treated for 36 months (6 versus 3 distributions). Dried blood spots were collected at 36 months among children ages 1–5 years, and MSP-119 antibody levels were assessed using a bead-based multiplex assay to measure malaria seroprevalence.

Results: Antibody results were available for 991 children. MSP-119 seropositivity was 62.7% in the biannual distribution arm compared to 68.7% in the annual arm (prevalence ratio 0.91, 95% CI 0.83 to 1.00). Mean semi-quantitative antibody levels were lower in the biannual distribution arm compared to the annual arm (mean difference −0.39, 95% CI −0.05 to −0.72).

Conclusions: Targeted biannual azithromycin distribution was associated with lower malaria seroprevalence compared to that in a population that received annual distribution.

Trial Registration Clinicaltrials.gov NCT00792922

Keywords: Malaria, Azithromycin, Niger, Mass drug administration

Background

Biannual mass azithromycin administration has been shown to decrease all-cause post-neonatal child mortality in some settings in sub-Saharan Africa [1, 2]. Annual mass azithromycin distribution to entire communities is highly effective at clearing the ocular strains of chlamydia that cause blinding trachoma [3–5]. Since 1999, over 750 million doses of azithromycin have been distributed to trachoma-endemic districts [6, 7]. Mass drug administration (MDA) with azithromycin as part of trachoma elimination programmes has been shown to reduce the burden of other childhood infections, including diarrhoea [8].

*Correspondence: catherine.oldenburg@ucsf.edu

1 Francis I Proctor Foundation, University of California, San Francisco, San Francisco, CA, USA

Full list of author information is available at the end of the article
lower respiratory infection [9], and in some studies malaria [10, 11], possibly contributing to observed reductions in child mortality [12, 13].

Azithromycin has modest activity against *Plasmodium falciparum*, the most virulent human malaria parasite, due to action against the parasite apicoplast [14–17]. Previous studies assessing the effect of azithromycin MDA on malaria infection yielded contradictory conclusions. In Tanzania, malaria prevalence decreased transiently in the month following azithromycin MDA [11]. Previously, in the Partnership for the Rapid Elimination of Trachoma (PRET)-Niger study, lower malaria parasitaemia prevalence was documented in communities that had received two biannual azithromycin MDAs compared to communities receiving one annual MDA [10]. However, there was no difference in parasitaemia after 36 months of biannual versus annual MDA [18, 19]. These studies measured malaria infection via thick smear, 6 to 12 months after the last antibiotic dose, when trachoma measurements are typically performed in trachoma trials. The effect of a single dose of azithromycin for malaria would likely occur over a shorter time period, and thus a single measure of malaria infection many months after treatment may not be an ideal measure of the overall effect of azithromycin on malaria incidence. Thick smear will also not detect low-intensity infections [20]. Alternative measures of malaria exposure and transmission may therefore be useful in evaluating the effect of azithromycin for malaria as an off-target effect of azithromycin for trachoma control.

Antibody measurements have been proposed as markers of malaria exposure over time [21–23]. Population seroprevalence to merozoite surface protein 1 (MSP-1), a dominant antigen of asexual *P. falciparum*, is predicted to provide information about malaria incidence beyond point prevalence by integrating serologic responses at different time points [21–25]. While serologic markers are not direct measures of clinical burden, they provide seroprevalence and age-seroprevalence curves give insights into exposure and transmission patterns [22, 25]. Here, the effect of biannual distribution of azithromycin to children was compared to annual distribution to the entire community, each over three years, on the burden of malaria using serologic markers of *P. falciparum* exposure in preschool-aged children in Niger.

**Methods**

**Ethical approval**

Ethical approval was obtained from the Committee on Human Research at the University of California, San Francisco and the Comité d’Ethique du Niger. Verbal informed consent was obtained from local chiefs of each study community and from the parent or guardian of each study participant. CDC staff did not have contact with study personnel or access to personal identifying information and were determined to not be engaged in human subjects research.

**Study design**

PRET was a series of community-randomized trials in Niger, The Gambia, and Tanzania designed to assess mass azithromycin distribution strategies for trachoma control (clinicaltrials.gov NCT00792922). In the present report, data from the Niger trial only were included [26–28]. The Niger trial was a 2 × 2 factorial trial of standard versus enhanced coverage and annual versus biannual distribution of azithromycin for trachoma control. In Niger, communities were randomized to one of four arms in a 1:1:1:1 fashion: (1) annual treatment of all individuals in the community with a treatment coverage target of 80%; (2) annual treatment of all individuals in the community with an enhanced treatment coverage target of 90%; (3) biannual treatment of children aged 12 and under with a treatment coverage target of 80%; or (4) biannual treatment of children aged 12 and under with an enhanced treatment coverage target of 90%. Communities were randomized by stratified block randomization within each Centre de Santé Intégrée (CSI) by high or low trachoma prevalence, as previously described [26]. The present report is restricted only to the enhanced coverage arms, as dried blood spots for antibody tested were only collected in these arms. The remainder of this report is, therefore, focused only on the enhanced distribution study arms. Communities were eligible for inclusion in the study if they had a population between 250 and 600 at the most recent government census (done in 2001 with population sizes in 2010 estimated based on projected population growth) and clinical trachoma prevalence of at least 10% at the time of the census.

**Study setting**

Study communities were located in Matamèye District, Zinder Region and were treated from May 2010 until May 2013. This region is situated in the Sahel and has highly seasonal malaria incidence, with peak transmission shortly after the peak in rainfall, typically in September [29, 30]. At the time of the study, there was no seasonal malaria chemoprevention programme in this region, although a bed net distribution programme was active. Annual distributions occurred in June/July, at the beginning of the high transmission season. In the biannual distribution arm, communities were additionally treated in December/January, during the low transmission season. Data for the present analysis was collected in September 2013.
Intervention

Prior to each MDA, a door-to-door enumerative census was undertaken in all study communities, which formed the sampling frame for treatment and evaluation. In all communities included in this report, each MDA occurred over a 1- to-4-day period: up to three follow-up visits occurred after the initial MDA day in an attempt to achieve coverage of 90% or greater. In the annual MDA arm, communities received a total of three rounds of MDA distributed via a door-to-door program to all individuals, regardless of age. In the biannual MDA communities, children aged 6 months to 12 years received a total of six rounds of door-to-door MDA; no one over the age of 12 was treated in these communities. During each MDA, all eligible participants were offered a single dose of directly observed oral azithromycin (20 mg/kg up to a maximum dose of 1 g in adults). Children under 6 months of age or those with macrolide allergy were offered topical tetracycline ointment (1%) for 6 weeks. In the annual treatment arm, pregnant women were offered tetracycline ointment.

Serology assessment

In each study community, a random sample of 50 children aged 0 to 5 years were selected to have samples collected. Dried blood spots were only collected in children aged 1 to 5 years of age due to the presence of maternal antibodies. Blood samples were collected via finger or heel stick in September 2013. Dried blood spots based on the most recent census [31] were analysed for antibody response to a portion of the P. falciparum antigen MSP-119 using a multiplex bead array assay on a Luminex 200 platform. Results were reported as the median fluorescence intensity (MFI) minus background (MFI-BG), where background is the signal from beads with buffer only. The seropositivity cutoff was MFI-BG ≥ 1758 as determined by receiver operator characteristic curve analysis using a positive panel of serum from US-residents who had never experienced microscopists at the Zinder Regional Hospital. Discrepancies were adjudicated by a third reader. Microscopists determined the presence or absence of P. falciparum parasites and counted the number of asexual parasites per 200 white blood cells (assuming a white blood cell count of 8000/µl). Each child’s tympanic temperature was assessed at the time of blood collection. Clinically symptomatic malaria was defined as a blood slide positive for P. falciparum accompanied by tympanic temperature ≥ 38.5 °C. The geometric mean of the two parasite densities was used for analysis. Haemoglobin concentration was measured for all children (HemoCue AB, Angelholm, Sweden).

Sample size

The trial was powered for the primary trachoma outcome [26]. An a priori sample size calculation was not performed for this non-prespecified secondary outcome.

Statistical methods

All analyses were conducted as intention-to-treat. Descriptive statistics were calculated by study arm with medians and interquartile ranges (IQR) or proportions. A log₁₀ transformations of MFI-BG (as a semi-quantitative indicator of antibody levels) and parasite density was used for analysis. Parasite prevalence, clinically symptomatic malaria prevalence, and sero-prevalence of MSP-119-specific antibodies and corresponding binomial 95% confidence intervals (CI) were calculated at the community level. Prevalence ratios (PR) for the association between malaria infection and MSP-119 seropositivity were calculated using generalized linear mixed models with a binomial distribution and log link with a random effect for the study community to account for clustering within communities, and adjusted for age and gender [32, 33].

To assess the difference in seropositivity to MSP-1 by study arm, generalized linear mixed model with a binomial distribution and log link were used to estimate risk ratios, with a random effect for study community. To assess differences in quantitative antibody levels, a log₁₀ transformation of the MSP-1 MFI-BG values was used. Generalized linear mixed models with a Gaussian distribution and identity link were used to estimate the mean difference in antibody level between study arms, with a random effect for study community. Differences in the age-seroprevalence and semi-quantitative antibody curves were evaluated to assess differences in short- and long-term malaria exposure in a generalized linear model with binomial (seropositivity) or Gaussian (MFI-BG) distribution, with a study arm by age category interaction term, with age treated as a continuous variable. All analyses were conducted in R (version 3.4.3, The R Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 991 children contributed MSP-1 serologic data, of whom 460 were in annual azithromycin distribution communities and 531 in biannual azithromycin distribution communities (Fig. 1). The distribution of participant and baseline community characteristics was balanced between study arms (Table 1). Median age of children selected for sample collection was 3 years,
with an equal distribution of children of age 1–5 years. Azithromycin MDA coverage in the study communities has been previously reported and exceeded 90% among children aged 6–59 months at each time point [18]. In September 2013 at the 36-month study visit, half of the children (55.2%, 95% CI 52.1 to 58.3%) had a positive thick smear for malaria parasites, and prevalence of malaria was 7.0% (95% CI 5.5 to 8.7%). As previously reported, there were no significant differences in malaria infection or clinically symptomatic malaria prevalence by study arm [18, 19]. Seropositivity against MSP-1 19 was 65.5% (95% CI 62.5% to 68.4%). The prevalence of malaria infection and seropositivity increased with increasing age (PR 1.09 per one-year increase in age, 95% CI 1.06 to 1.13, P<0.001), but the prevalence of clinically symptomatic malaria did not (PR 1.14 per 1-year increase in age, 95% CI 0.95 to 1.36, P=0.16). Figure 2 shows the relationship between malaria seroprevalence and infection and parasite density and mean MSP-1 19 titre. MSP-1 19 seropositivity was higher among children with malaria infection (PR 1.23, 95% CI 1.04 to 1.44, P=0.01) compared to those without infection, but not among those with clinically symptomatic malaria (PR=1.20, 95% CI 0.70 to 1.59, P=0.19) compared to those without clinically symptomatic malaria.

MSP-1 19 seroprevalence was 9% lower (PR 0.91, 95% CI 0.83 to 1.00, P=0.047) among 1–5-year-olds from communities in which children received biannual treatment compared to those from communities receiving annual treatment. Mean MFI-BG was also lower in 1–5-year-olds in biannual MDA communities than children in communities receiving annual MDA (mean difference −0.17, 95% CI −0.02 to −0.32, P=0.04) (Fig. 3). There was no evidence that malaria exposure differed by age as assessed by age-seroprevalence (P=0.94, age-by-arm interaction; Fig. 3) or MFI-BG by age curve (P=0.35, age-by-arm interaction) between children in communities receiving biannual versus annual azithromycin.

### Discussion

Biannual distribution of azithromycin targeted to children was associated with lower antibody-based measures of exposure to *P. falciparum* compared to annual distribution to the entire community. In these same communities, no difference in *P. falciparum* infection prevalence after 36 months of treatment was reported [18]. The antibody response to MSP-1 19 is long-lived [22] and is potentially a more sensitive indicator than microscopy point prevalence of cumulative malaria incidence. Thus, these results suggest that serologic markers of malaria exposure were slightly lower in areas receiving biannual compared to annual treatment with azithromycin.

The small (9%) reduction in MSP-1 19 seroprevalence documented in this study between biannually

### Table 1 Descriptive characteristics of communities (at baseline) and children providing dried blood spots for serologic assessments (at 36 months)

| Study arm | Biannual azithromycin | Annual azithromycin |
|-----------|------------------------|----------------------|
| **Community characteristics** | | |
| No. communities | 12 | 12 |
| No. children/community, mean | 66 (range 36 to 124) | 72 (range 37 to 119) |
| Proportion female, % (95% CI) | 49.0% (45.1 to 52.9) | 52.1% (49.3 to 54.8) |
| Age, months (95% CI) | 18.7 (17.4 to 19.9) | 18.4 (17.3 to 19.4) |
| **Individual characteristics** | | |
| No. individuals | 531 | 460 |
| Age, years | | |
| 1 | 113 (21%) | 99 (22%) |
| 2 | 105 (20%) | 87 (19%) |
| 3 | 89 (17%) | 84 (18%) |
| 4 | 113 (21%) | 86 (19%) |
| 5 | 111 (21%) | 104 (23%) |
| Female gender | 275 (52%) | 231 (50%) |
| *P. falciparum* infection | 291 (55%) | 256 (56%) |
| Clinically symptomatic *P. falciparum* infection plus fever | 33 (6%) | 36 (8%) |
| *P. falciparum* parasite density, median (IQR) | 0 (0 to 1340) | 0 (0 to 2960) |
| *P. falciparum* parasite density among children with infection, median (IQR) | 1100 (240 to 5815) | 2320 (470 to 8030) |
| Haemoglobin, g/dL, median (IQR) | 9.5 (8.4 to 10.4) | 9.4 (8.2 to 10.5) |
| MSP-1 19 seroprevalence | 333 (63%) | 316 (69%) |
and annually treated communities diverges from previous reports that have indicated a 44 to 73% decrease in malaria infection prevalence 1 month after azithromycin treatment [11, 34]. Compared with short-term effects of azithromycin on malaria infection, more modest reductions in antibody-based measures of \textit{P. falciparum} exposure would be expected since the outcomes reflect differences in cumulative exposure between groups, averaged over a longer period of time. However, the intensity of transmission in holoendemic regions may make it difficult to detect differences in malaria seropositivity, particularly as children age and their probability of previous exposure increases. In holoendemic settings, short-acting interventions may also have less effect on transmission due to the ubiquity of infection. Among young children in particular, antibody responses may be lost, which could affect sensitivity to seasonal trends [35, 36]. The results of this study suggest that longer-term effects of azithromycin for malaria may be more modest than short-term effects.

Azithromycin has modest in vitro activity against \textit{P. falciparum} due to targeting the plasmodial apicoplast [15,
and thus a reduction in malaria burden is a plausible mechanism for the reduction in mortality observed following azithromycin distribution [1, 12, 13, 38]. In the same study area as the present analysis, biannual mass azithromycin distribution led to a reduction in mortality due to infection causes among preschool children. No difference in mortality due to malaria was noted, but this assessment was based on verbal autopsy [38], which can suffer from misclassification and poor sensitivity for malaria diagnosis [39, 40]. Additionally, the study was not powered to detect a difference in malaria-specific mortality. The results shown here suggest that malaria incidence is impacted by additional doses of azithromycin, which may indicate that reduction in malaria contributes to observed decreases in all-cause mortality following azithromycin distribution. However, the precise mechanism of action for the observed reduction in mortality following azithromycin distribution remains unclear. Some evidence suggests that the effect of azithromycin on malaria prevalence is transient [41]. Azithromycin likely also leads to reductions in other pathogenic organisms which may contribute to overall mortality effects. For example, the prevalence of *Campylobacter* species, an important cause of diarrhea and diarrhea-related mortality, was reduced in children in communities receiving biannual azithromycin compared to placebo in Niger [42]. Any effect of azithromycin on mortality that is mediated via changes in malaria transmission likely occurs in the context of alteration of transmission of other pathogenic organisms, and the overall effect of azithromycin distribution on mortality may or may not be due in part to small changes in malaria transmission.

The results of this study must be considered in the context of several limitations. First, there was no untreated control group, and thus the quantitative impact of azithromycin distribution cannot be determined. Second, biannual treatment of children under age 12 was compared to annual treatment of all individuals in the community, and so did not compare biannual versus annual treatment in the same age group. Third, mass azithromycin distributions occurred at the beginning of the high transmission season and the low transmission season. Malaria transmission is highly seasonal in Niger, and treatment targeted specifically during the high transmission season may have had a larger effect than treatment during the low transmission season. However, a single dose of azithromycin during the high transmission season may also paradoxically have reduced effect compared to treatment during the low transmission season due to the high parasite load and frequency of infection during the high transmission season [43]. Fourth, the generalizability of these results is limited only to preschool children in the setting of highly seasonal malaria transmission.

Future studies could evaluate the impact of azithromycin MDA on malaria incidence in older children or adults.

**Conclusions**

The results of this study are consistent with a small reduction in *P. falciparum* exposure in communities in Niger receiving targeted biannual azithromycin in children compared to those receiving annual azithromycin distribution to entire communities. Thus, mass treatment with azithromycin may lead to a decrease in malaria incidence in young children, presumably contributing to the survival benefits afforded by azithromycin.

**Acknowledgements**

Not applicable.

**Disclaimer**

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

**Authors’ contributions**

CEO: design and conception; formal analysis; interpretation of results; drafting manuscript. AA: design and conception; data collection; interpretation of results; critical revision of manuscript. GC: performed laboratory experiments; interpretation of results; critical revision of manuscript. BK: design and conception; data collection; interpretation of results; critical revision of manuscript. BN: design and conception; data collection; interpretation of results; critical revision of manuscript. PN: design and conception; data collection; interpretation of results; critical revision of manuscript. BD: design and conception; data collection; interpretation of results; critical revision of manuscript. YY: design and conception; data collection; interpretation of results; critical revision of manuscript. AG: design and conception; data collection; interpretation of results; critical revision of manuscript. DLM: design and conception; design and conduct of laboratory experiments; interpretation of results; drafting manuscript. All authors read and approved the final manuscript.

**Funding**

This study was supported by the Bill and Melinda Gates Foundation. CEO was supported by part by a Research to Prevent Blindness Career Development Award. The funders had no role in the design of the study, data collection, analysis, or interpretation of data in the writing of the manuscript or the decision to publish.

**Availability of data and materials**

The datasets used during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Ethical approval was obtained from the Committee on Human Research at the University of California, San Francisco and the Comité d’Éthique du Niger. Verbal informed consent was obtained from local chiefs of each study community and from the parent or guardian of each study participant. CDC staff did not have contact with study personnel or access to personal identifying information and were determined to not be engaged in human subjects research.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
References

1. Keenan JD, Bailey RL, West SK, Arzika A, Hart J, Weaver J, et al. Mass azithromycin distribution for reducing childhood mortality in sub-Saharan Africa. N Engl J Med. 2018;378:1583–92.

2. Oldenburg CE, Arzika AM, Amza A, Gebe T, Kalu A, Maringo Z, et al. Mass azithromycin distribution to prevent childhood mortality: a pooled analysis of cluster randomized trials. Am J Trop Med Hyg. 2019;100:691–5.

3. Solomon AW, Holland MJ, Alexander NDE, Massae PA, Aguirre A, Natividad-Sancho A, et al. Mass Treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351:1962–71.

4. Chidambaram JD, Almeida W, Melese M, Lakew T, Yi EH, House JI, et al. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA. 2006;295:1142–6.

5. Schacht J, West SK, Mabey D, Dawson CR, Bobo L, Bailey R, et al. Azithromycin in control of trachoma. Lancet. 1999;354:630–5.

6. Emerson PM, Reeder PJ, Sarah V. Progress and projections in the program to eliminate trachoma. PLoS Negl Trop Dis. 2017;11:e0005042–4.

7. International Trachoma Initiative: Frequently Asked Questions.

8. Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, Griffin J, et al. Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar J. 2008;7:195.

9. Guillebaud J, Mahamadou A, Zamanka H, Katzelma M, Arzika I, Ibrahim ML, et al. Epidemiology of malaria in an area of seasonal transmission in Niger and implications for the design of a seasonal malaria chemoprevention strategy. Malar J. 2013;12:379.

10. Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, Griffin J, et al. Effects of azithromycin on malarial antibody density models. Malar J. 2016;15:79.

11. Schachterle SE, Mtove G, Levens JP, Clemens E, Shi L, Raj A, et al. Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, Tanzania. Emerg Infect Dis. 2014;20:1–9.

12. Porco TC, Gebe T, Ayele B, House J, Keenan J, Zhou Z, et al. Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: a randomized trial. JAMA. 2009;302:962–8.

13. Keenan JD, Ayele B, Gebe T, Zerihun M, Zhou Z, House JI, et al. Childhood mortality in a cohort treated with mass azithromycin for trachoma. Clin Infect Dis. 2011;52:883–8.

14. Rosenthal PJ. Azithromycin for malaria? Am J Trop Med Hyg. 2016;95:2–4.

15. Siddhu ABS, Sun Q, Nkrunum LJ, Dunne MW, Sasschetti JC, Fidock DA. In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J Infect Dis. 2007;196:2494–504.

16. Dah E, Rosenthal PJ. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother. 2007;51:3485–90.

17. Gaillard T, Dormio J, Madamat M, Pradines B. Macrolides and associated antibiotics based on similar mechanism of action like lincosamides in malaria. Malar J. 2016;15:85.
40. Setel PW, Whiting DR, Hemed Y, Chandramohan D, Wolfson LJ, Alberti KGMM, et al. Validity of verbal autopsy procedures for determining cause of death in Tanzania. Trop Med Int Heal. 2006;11:681–96.
41. Bloch EM, Munoz B, Mrango Z, Weaver J, Mboeta LEG, Lietman TM, et al. The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: a prospective study. Malar J. 2019;18:284.
42. Doan T, Hinterwirth A, Worden L, Arzika AM, Malik R, Abdou A, et al. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution. Nat Med. 2019;25:1370–6.
43. Gao D, Amza A, Nassirou B, Kadri B, Sippl-Swezey N, Liu F, et al. Optimal seasonal timing of oral azithromycin for malaria. Am J Trop Med Hyg. 2014;91:936–42.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.